Cerus Corp (CERS) - Financial and Strategic SWOT Analysis Review

Cerus Corp (CERS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description - A detailed description of the company’s operations and business divisions
• Corporate strategy - Analyst’s summarization of the company’s business strategy
• SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats
• Company history - Progression of key events associated with the company
• Major products and services - A list of major products, services and brands of the company
• Key competitors - A list of key competitors to the company
• Key employees - A list of the key executives of the company
• Executive biographies - A brief summary of the executives’ employment history
• Key operational heads - A list of personnel heading key departments/functions
• Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company
• Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history
• Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history

Highlights

Cerus Corp (Cerus) is a biomedical products company that focuses on the field of blood transfusion safety. It develops and commercializes Intercept blood system, which reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria, and parasites present in donated blood. The Intercept blood system is for use with blood components including platelets, plasma, and red blood cells. It is also used to produce PRCFC, and pathogen reduced plasma and cryoprecipitate. The company markets and sells the Intercept blood system through its direct sales force and distributors in several countries including the US, Europe, the Commonwealth of Independent States (CIS), Latin America, the Middle East, and selected countries in other regions. Cerus is headquartered in Concord, California, the US.

Cerus Corp Key Recent Developments

Feb 22, 2022: Cerus Announces Record Fourth Quarter and Full-Year 2021 Financial Results
Jan 10, 2022: Cerus announces record preliminary fourth quarter and full-year 2021 product revenue and provides business update
Jan 10, 2022: Cerus Announces Record Preliminary Fourth Quarter and Full-Year 2021 Product Revenue and Provides Business Update
Sep 20, 2021: Cerus Corp Announces INTERCEPT Fibrinogen Complex Customer Presentations at SABM Virtual Annual Meeting 2021
Aug 04, 2021: Cerus Corporation Announces Appointment of Ann Lucena to Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs

Note: Some sections may be missing if data is unavailable for the company